Floatz logo

Ticagrelor

Cardiovascular Death

AstraZenecaSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Cardiovascular Death cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Ticagrelor is also rated in:

myocardial infarctionDormant
BBB
Indicative ·
78 / 100
View asset →
ischemic strokeDormant
BBB
Indicative ·
76 / 100
View asset →
transient ischemic attackDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →